Eli Lilly & Company Foundation

Indianapolis, United States
Non-Profit
Active
Total investments

15

Average round size

49M

Portfolio companies

15

Rounds per year

0.27

Lead investments

3

Areas of investment
BiotechnologyHealth CareCommunitiesGeneticsMedicalLife ScienceTherapeuticsNon ProfitBiopharmaBioinformatics

Investor highlights

Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
15
Lead investments
3
Rounds per year
0.27
Investments by industry
  • Biotechnology (12)
  • Therapeutics (5)
  • Biopharma (3)
  • Health Care (3)
  • Medical (3)
  • Show 6 more
Investments by region
  • United States (14)
  • United Kingdom (1)
Peak activity year
2022

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Group Appearance index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company nameDeal dateIndustryDeal stageDeal sizeLocation
Ajax Therapeutics13 May 2024Biotechnology, Medical, Life ScienceLate Stage Venture95MUnited States, Massachusetts, Cambridge
Fountain Therapeutics18 Nov 2021Biotechnology, Health Care, TherapeuticsEarly Stage Venture15MUnited States, California, San Francisco
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.